H. Kennecke, R. Yerushalmi, R. Woods, M. Cheang, D. Voduc et al., Metastatic behavior of breast cancer subtypes, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, pp.3271-3278, 2010.

P. W. Sperduto, N. Kased, D. Roberge, Z. Xu, R. Shanley et al., Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases, Int J Radiat Oncol Biol Phys, vol.82, pp.2111-2118, 2012.

H. Gauthier, M. N. Guilhaume, F. C. Bidard, J. Y. Pierga, V. Girre et al., Survival of breast cancer patients with meningeal carcinomatosis, Ann Oncol Off J Eur Soc Med Oncol, vol.21, pp.2183-2190, 2010.

E. Le-rhun, S. Taillibert, F. Zairi, N. Kotecki, P. Devos et al., A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer, J Neurooncol, vol.113, 2013.

S. Yust-katz, P. Garciarena, D. Liu, Y. Yuan, N. Ibrahim et al., Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis, J Neurooncol, vol.114, 2013.

A. Niwi-nska, H. Rudnicka, and M. Murawska, Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intracerebrospinal fluid chemotherapy, Clin Breast Cancer, vol.15, pp.66-72, 2015.

E. Le-rhun, M. Weller, D. Brandsma, M. Van-den-bent, E. De-azambuja et al., Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours, Ann Oncol Off J Eur Soc Med Oncol, vol.28, pp.84-99, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02940542

N. U. Lin, C. E. Sohl, J. Razzak, A. R. Arnaout, A. Winer et al., Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases, Cancer, vol.113, 2008.

A. M. Brufsky, M. Mayer, H. S. Rugo, P. A. Kaufman, E. Tan-chiu et al., Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, 2011.

K. Slimane, F. Andre, S. Delaloge, A. Dunant, A. Perez et al., Risk factors for brain relapse in patients with metastatic breast cancer, Ann Oncol Off J Eur Soc Med Oncol, vol.15, pp.1640-1644, 2004.

R. Lai, C. T. Dang, M. G. Malkin, and L. E. Abrey, The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma, Cancer, vol.101, pp.810-816, 2004.

A. J. Clayton, S. Danson, S. Jolly, W. Ryder, P. A. Burt et al., Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer, Br J Cancer, vol.91, pp.639-682, 2004.

J. C. Bendell, S. M. Domchek, H. J. Burstein, L. Harris, J. Younger et al., Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma, Cancer, vol.97, pp.2972-2979, 2003.

L. , Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, pp.5278-86, 2009.

J. H. Ahn, S. H. Lee, S. Kim, J. Joo, H. Yoo et al., Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection, J Neurosurg, vol.116, pp.984-93, 2012.

T. C. Van-der-ree, D. W. Dippel, C. J. Avezaat, S. Smitt, P. A. Vecht et al., Leptomeningeal metastasis after surgical resection of brain metastases, J Neurol Neurosurg Psychiatry, vol.66, pp.225-232, 1999.

S. Abouharb, J. Ensor, M. E. Loghin, R. Katz, S. L. Moulder et al., Leptomeningeal disease and breast cancer: the importance of tumor subtype, Breast Cancer Res Treat, vol.146, pp.477-86, 2014.

B. Kö-berle, B. Koch, B. M. Fischer, and A. Hartwig, Single nucleotide polymorphisms in DNA repair genes and putative cancer risk

, Arch Toxicol, vol.90, 2016.

P. Liu, H. Cheng, T. M. Roberts, and J. J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat Rev Drug Discov, vol.8, pp.627-671, 2009.

M. Cizkova, S. Vacher, D. Meseure, M. Trassard, A. Susini et al., PIK3R1 underexpression is an independent prognostic marker in breast cancer, BMC Cancer, vol.13, p.545, 2013.

D. A. Fruman and C. Rommel, PI3K and cancer: lessons, challenges and opportunities, Nat Rev Drug Discov, vol.13, pp.140-56, 2014.

K. D. Courtney, R. B. Corcoran, and J. A. Engelman, The PI3K pathway as drug target in human cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, pp.1075-83, 2010.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, 2011.

B. Beagle and D. A. Fruman, A lipid kinase cousin cooperates to promote cancer, Cancer Cell, vol.19, 2011.

A. Soler, H. Serra, W. Pearce, A. Angulo, J. Guillermet-guibert et al., Inhibition of the p110a isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis, J Exp Med, vol.210, 2013.

E. Hirsch, E. Ciraolo, I. Franco, A. Ghigo, and M. Martini, PI3K in cancer-stroma interactions: bad in seed and ugly in soil, Oncogene, vol.33, pp.3083-90, 2014.

I. Hohensee, H. Chuang, A. Grottke, S. Werner, A. Schulte et al., PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression, Oncotarget, vol.8, pp.6155-68, 2017.

J. Baselga, Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer, Oncol, vol.16, 2011.

I. Hohensee, K. Lamszus, S. Riethdorf, S. Meyer-staeckling, M. Glatzel et al., Frequent genetic alterations in EGFR-and HER2-driven pathways in breast cancer brain metastases, Am J Pathol, vol.183, 2013.

B. Adamo, A. M. Deal, E. Burrows, J. Geradts, E. Hamilton et al., Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases, Breast Cancer Res BCR, vol.13, 2011.

R. Nosaka, F. Yamasaki, T. Saito, T. Takayasu, M. Kolakshyapati et al., Role for loss of nuclear PTEN in a harbinger of brain metastases, J Clin Neurosci Off J Neurosurg Soc Australas, vol.44, pp.148-54, 2017.

K. Pfisterer, A. Fusi, K. Klinghammer, M. Knö-dler, A. Nonnenmacher et al., PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximabdocetaxel, Head Neck, vol.37, pp.471-479, 2015.

M. Hildebrandt, H. Yang, M. Hung, J. G. Izzo, M. Huang et al., Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, pp.857-71, 2009.

M. Chen, J. Gu, G. L. Delclos, A. M. Killary, Z. Fan et al., Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients, Carcinogenesis, vol.31, pp.1387-91, 2010.

Q. Li, J. Yang, Q. Yu, H. Wu, B. Liu et al., Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with nonsmall cell lung cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, 2013.

E. Ló-pez-knowles, O. 'toole, S. A. Mcneil, C. M. Millar, E. Qiu et al., PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality, Int J Cancer, vol.126, pp.1121-1152, 2010.